CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.431
EU - Europa 2.934
AS - Asia 2.334
SA - Sud America 288
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 110
OC - Oceania 17
Totale 9.226
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.341
RU - Federazione Russa 1.261
SG - Singapore 892
CN - Cina 455
IT - Italia 452
GB - Regno Unito 252
HK - Hong Kong 239
BR - Brasile 233
DE - Germania 226
VN - Vietnam 189
FR - Francia 154
IE - Irlanda 152
FI - Finlandia 115
SE - Svezia 115
IN - India 98
JP - Giappone 78
BD - Bangladesh 77
KR - Corea 77
ES - Italia 49
CA - Canada 46
ID - Indonesia 46
NL - Olanda 40
IQ - Iraq 37
SA - Arabia Saudita 32
TR - Turchia 27
TG - Togo 25
UA - Ucraina 21
AR - Argentina 20
MX - Messico 20
AT - Austria 19
BJ - Benin 19
BE - Belgio 17
NG - Nigeria 16
EG - Egitto 15
ZA - Sudafrica 13
AU - Australia 11
PL - Polonia 11
PK - Pakistan 10
PH - Filippine 9
CH - Svizzera 8
EC - Ecuador 8
IL - Israele 8
IR - Iran 8
HU - Ungheria 7
MY - Malesia 7
CL - Cile 6
CR - Costa Rica 6
TW - Taiwan 6
AL - Albania 5
GR - Grecia 5
GT - Guatemala 5
KE - Kenya 5
MA - Marocco 5
UY - Uruguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CO - Colombia 4
NZ - Nuova Zelanda 4
VE - Venezuela 4
BH - Bahrain 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
JM - Giamaica 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
TN - Tunisia 3
AG - Antigua e Barbuda 2
BN - Brunei Darussalam 2
DK - Danimarca 2
DM - Dominica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
NI - Nicaragua 2
NP - Nepal 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
ET - Etiopia 1
GF - Guiana Francese 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
Totale 9.106
Salva come PNG Salva come JPEG
Città #
Dallas 637
Singapore 453
Moscow 440
San Jose 423
Ashburn 399
Chandler 244
Hong Kong 231
Council Bluffs 178
Dublin 139
Verona 118
Munich 112
Beijing 106
New York 91
The Dalles 89
Southend 87
Ho Chi Minh City 73
Helsinki 69
Los Angeles 68
London 46
Milan 45
Jacksonville 44
Hanoi 37
Lawrence 34
Princeton 34
Paris 32
Buffalo 31
Lappeenranta 31
Jakarta 30
Redondo Beach 30
Rome 30
Santa Clara 30
Wilmington 28
São Paulo 27
Amsterdam 25
Lomé 25
Chennai 24
Frankfurt am Main 22
Manchester 22
Tokyo 22
Riyadh 21
Madrid 20
Sindelfingen 20
Woodbridge 20
Bologna 19
Cotonou 19
Washington 19
Houston 18
Mumbai 18
Najaf 18
Jinan 17
Monza 16
Phoenix 16
Seattle 16
Abuja 15
Atlanta 15
Shanghai 15
Chicago 14
Nuremberg 14
Orem 14
Boston 13
Haiphong 13
Barcelona 12
River Grove 12
Bethnal Green 11
Ghaziabad 11
Nanjing 11
Warsaw 11
Ann Arbor 10
Guangzhou 10
Liverpool 10
Montreal 10
Toronto 9
Ankara 8
Brasília 8
Brussels 8
Dongguan 8
Islington 8
Redwood City 8
Tianjin 8
Vancouver 8
Bari 7
Cairo 7
Chieri 7
City of London 7
Denver 7
Fairfield 7
Giza 7
Marseille 7
Mexico City 7
Naples 7
Vienna 7
Wakabadai 7
Baghdad 6
Brooklyn 6
Budapest 6
Delhi 6
Gurugram 6
Hyderabad 6
Igusa 6
Istanbul 6
Totale 5.289
Salva come PNG Salva come JPEG
Nome #
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 365
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 352
A systematic review of treatments for pityriasis lichenoides 343
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 265
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 255
Gender perspective in the management of psoriasis 194
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 180
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 177
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 171
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 166
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 164
A case of genital primary syphilis with superimposed impetigo 158
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 158
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 153
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 149
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 143
A man with a widespread bullous eruption 138
Amicrobial Pustulosis of the Folds: Report of Three New Cases 136
Advanced Glycation End Products and Psoriasis 135
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 135
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 134
Annular Erythema: New and Revisited Variants 134
Idiopathic lichenoid and granulomatous dermatitis 131
Uncommon Non‑Infectious Annular Dermatoses 130
Adrenergic urticaria successfully treated with omalizumab 130
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 129
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 128
Clinical profile and co-infections of urethritis in males 127
Price variability of TNF-α inhibitor biosimilars among European countries 121
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 118
Biological agents targeting interleukin-13 for atopic dermatitis 118
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 115
Interferon-beta injection site reactions in patients with multiple sclerosis. 115
Atopic Dermatitis in the Elderly Population 114
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 113
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 112
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 108
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 105
Managing the Patient with Psoriasis and Metabolic Comorbidities 105
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 105
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 105
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 105
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 102
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 98
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 96
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 95
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 94
Eosinophilic annular erythema successfully treated with cyclosporine 90
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 89
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 88
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 86
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 85
Pruritus as a Distinctive Feature of Type 2 Inflammation 81
null 80
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 80
Visual Vignette 80
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 79
Targeting IL-4 for the Treatment of Atopic Dermatitis 79
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 76
Tailored biological treatment for patients with moderate-to-severe psoriasis 75
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 73
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 72
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 71
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 69
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 68
Overview of Atopic Dermatitis in Different Ethnic Groups 67
The Combination of Dupilumab with Other Monoclonal Antibodies 67
FARMACOECONOMIA APPLICATA ALLE MALATTIE INFIAMMATORIE CRONICHE CUTANEE (PSORIASI E DERMATITE ATOPICA) 62
Lymphoplasmacytic plaque effectively treated with imiquimod 61
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 58
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 57
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 57
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 52
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study 51
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 42
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study 27
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 25
The Girl with a Pearl Earring: A dermatological puzzle 21
Klinische Merkmale und Behandlungen der transitorischen akantholytischen Dermatose (Morbus Grover): ein systematischer Review 20
Refractory Lichen Amyloidosis Successfully Treated with Upadacitinib: A Case Report and Literature Review 18
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence 17
Biosimilars for chronic plaque psoriasis: a 2026 update 15
Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis) 15
Real‑World Efficacy of IL‑23 Inhibitors in Psoriasis Affecting High‑Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) 15
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis) 9
Dermatologic manifestations in an adult with Williams syndrome 9
Real-world comparison of IL-23 inhibitors in moderate-to-severe plaque psoriasis: a focus on super responders—IL PSO (Italian landscape Psoriasis) 7
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate‐to‐Severe Atopic Dermatitis: A Multicentre Real‐World Study: IL‐AD (Italian Landscape Atopic Dermatitis) 5
Clinical Characteristics of Patients Presenting with Moderate-to-Severe Atopic Dermatitis and Concomitant Inflammatory Bowel Diseases: a Multicenter Retrospective Study 4
Totale 9.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.478
article - articoli 33.719
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 243
patent - brevetti 0
selected - selezionate 0
volume - volumi 516
Totale 68.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022215 0 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/20264.927 293 169 674 610 1.141 273 428 293 340 392 137 177
2026/2027436 276 160 0 0 0 0 0 0 0 0 0 0
Totale 9.226